Argos Therapeutics Inc. (NASDAQ:ARGS) shares dropped 7% on Monday . The stock traded as low as $6.20 and last traded at $6.34, with a volume of 110,419 shares traded. The stock had previously closed at $6.82.

ARGS has been the topic of several analyst reports. Piper Jaffray Cos. restated an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a report on Monday, June 20th. Stifel Nicolaus cut their price target on shares of Argos Therapeutics from $16.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 30th. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Argos Therapeutics in a report on Friday, June 17th. Zacks Investment Research upgraded shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a report on Friday, April 1st. Finally, Roth Capital boosted their price target on shares of Argos Therapeutics from $11.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, April 19th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $11.84.

The company’s market cap is $166.22 million. The firm’s 50-day moving average price is $6.20 and its 200-day moving average price is $5.50.

Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by $0.01. On average, equities analysts anticipate that Argos Therapeutics Inc. will post ($1.74) EPS for the current year.

Argos Therapeutics, Inc (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.